Showing results (431-440 of 523) with videos related to

Sort By:
Pageof 53
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2019
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint InhibitorsLizza E L Hendriks, Clemence Henon, Edouard Auclin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung CancerFilippo G Dall'Olio, Wael Zrafi, Damien Vasseur, et al.
Lung Cancer (Amsterdam, Netherlands)|October 24, 2025
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort studyIgor Gomez-Randulfe, Federico Monaca, Ornella Cantale, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 19, 2018
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung CancersAlexander Drilon, Jessica J Lin, Thomas Filleron, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 8, 2020
Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE TrialJulien Mazieres, Fabrice Barlesi, Isabelle Rouquette, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 30, 2026
Long-Term Impact of First-Line Amivantamab Plus Lazertinib Versus Osimertinib on Mechanisms of Acquired Resistance in MARIPOSA: A Brief ReportHidetoshi Hayashi, Byoung Chul Cho, David R Spigel, et al.
NPJ Precision Oncology|February 26, 2024
Genomic landscape of liquid biopsy mutations in TP53 and DNA damage genes in cancer patientsDamien Vasseur, Ahmadreza Arbab, Fabiola Giudici, et al.
The Journal of Clinical Investigation|December 28, 2018
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancerRoman M Chabanon, Gareth Muirhead, Dragomir B Krastev, et al.
Pageof 53